Bristol Myers Squibb & 2Seventy bio to discontinue enrollment in phase 3 KarMMa-9 Study

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM

Overview

Bristol Myers Squibb and 2seventy bio announced that the companies have made the difficult decision to discontinue enrollment in the phase 3 KarMMa-9 study investigating Abecma (idecabtagene vicleucel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response after autologous stem cell transplant.

KarMMa-9 Design

• The companies designed KarMMa-9 based on positive data from cohort 2c of the KarMMa-2 trial, which demonstrated a favourable benefit/risk profile for Abecma in a similar patient population.
• Since then, however, the NDMM treatment landscape has changed considerably with the evolution of more intense and prolonged induction therapies, resulting in fewer eligible patients for KarMMa-9.

The trial has been open for over one year in 18 countries but has faced enrollment challenges; despite numerous collaborative efforts with investigators and study staff to support recruitment, only 10% of the study population has been accrued to date.

From Clinical Development Department: Bristol Myers Squibb

• •Investigators indicate that due to advances in induction therapies, a significant majority – upwards of 70% – of patients with newly diagnosed multiple myeloma are now achieving a complete response or better following transplant,” said Anne Kerber, senior vice president, head of late clinical development, haematology, oncology and cell therapy (HOCT), Bristol Myers Squibb. 
• We celebrate this progress for patients while also recognizing that it reduces the eligible patient population for, and viability of, the KarMMa-9 trial.

Collaborative work

• BMS and 2seventy bio will work with investigators to determine appropriate next steps for patients currently enrolled in the KarMMa-9 study. 
•  We express our sincere gratitude to the patients who participated in the trial, and to the investigators and study staff for their collaboration.

The companies strongly believe in the value Abecma brings to patients and the important role it plays in the multiple myeloma treatment paradigm. BMS will continue to expand the reach of Abecma to as many patients globally as possible, both commercially and through ongoing bridging and combination studies.

Multiple myeloma: Key Area for Research

• Multiple myeloma is a key area of focus for BMS, and we remain committed to advancing the science to address unmet patient needs. 
• BMS is actively recruiting patients with multiple myeloma for several studies across four novel assets from our diverse cell therapy and protein degradation pipeline.

About the Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!